Search

Author/Creator Arranz, Jose Angel

2. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Issue 12 (December 2020)

Authors:
Powles, Thomas; van der Heijden, Michiel S; Castellano, Daniel; Galsky, Matthew D; Loriot, Yohann; Petrylak, Daniel P; Ogawa, Osamu; Park, Se Hoon; Lee, Jae-Lyun; De Giorgi, Ugo; Bögemann, Martin; Bamias, Aristotelis; Eigl, Bernhard J; Gurney, Howard; Mukherjee, Som D; Fradet, Yves; Skoneczna, Iw...
Journal:
Lancet oncology
Issue:
Volume 21:Issue 12(2020)
Page Start:
1574
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies. Issue 6 (3rd June 2018)

Authors:
Castellano, Daniel; Maroto, José Pablo; Espinosa, Enrique; Grande, Enrique; Bolós, M Victoria; Llinares, Julia; Esteban, Emilio; González del Alba, Aranzazu; Climent, Miguel Angel; Arranz, Jose Angel; Méndez, Mª José; Fernández Parra, Eva; Antón-Aparicio, Luis; Bayona, Cristina; Gallegos, Isabel;...
Journal:
Expert opinion on drug safety
Issue:
Volume 17:Issue 6(2018)
Page Start:
573
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Issue 7 (July 2021)

Authors:
Powles, Thomas; Csőszi, Tibor; Özgüroğlu, Mustafa; Matsubara, Nobuaki; Géczi, Lajos; Cheng, Susanna Y-S; Fradet, Yves; Oudard, Stephane; Vulsteke, Christof; Morales Barrera, Rafael; Fléchon, Aude; Gunduz, Seyda; Loriot, Yohann; Rodriguez-Vida, Alejo; Mamtani, Ronac; Yu, Evan Y; Nam, Kijoeng; Imai...
Journal:
Lancet oncology
Issue:
Volume 22:Issue 7(2021)
Page Start:
931
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Issue 9 (September 2022)

Authors:
Powles, Thomas; Tomczak, Piotr; Park, Se Hoon; Venugopal, Balaji; Ferguson, Thomas; Symeonides, Stefan N; Hajek, Jaroslav; Gurney, Howard; Chang, Yen-Hwa; Lee, Jae Lyun; Sarwar, Naveed; Thiery-Vuillemin, Antoine; Gross-Goupil, Marine; Mahave, Mauricio; Haas, Naomi B; Sawrycki, Piotr; Burgents, Jo...
Journal:
Lancet oncology
Issue:
Volume 23:Issue 9(2022)
Page Start:
1133
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer. (July 2019)

Authors:
Conteduca, Vincenza; Castro, Elena; Wetterskog, Daniel; Scarpi, Emanuela; Jayaram, Anuradha; Romero-Laorden, Nuria; Olmos, David; Gurioli, Giorgia; Lolli, Cristian; Sáez, Maria Isabel; Puente, Javier; Schepisi, Giuseppe; Salvi, Samanta; Wingate, Anna; Medina, Ana; Querol-Niñerola, Rosa; Marin-Agu...
Journal:
European journal of cancer
Issue:
Volume 116(2019)
Page Start:
158
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗